Navigation Links
Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
Date:4/28/2008

SANTA MONICA, Calif., April 28 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that the Company is compiling data for its Phase 2 testing results of Rh-Apo2L and expects to announce the findings within the next month. The Company previously announced that the target cancers for the drug have been determined and initial results are extremely positive. The cancer targets that the Company has chosen are ailments which Rh-Apo2L has shown the most efficacy and which have the most market potential. The Company previously announced that Rh-Apo2L testing results have shown strong efficacy in treating non-small cell lung cancer, non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer.

The Company intends to immediately file for Phase 3 clinical testing with the People's Republic of China's State Food and Drug Administration after the announcement of the findings from Phase 2 testing. The Company anticipates that the Chinese government will then allow for the commencement of Phase 3 testing within two to three months after the Phase 2 results are published. Phase 3 testing will entail large-volume tests on over 300 patients and is the last step before it may be commercially sold in the People's Republic of China.

About Rh-Apo2L- The Anti-Cancer Drug

Rh-Apo2L is a pioneering biotechnology gene therapy drug used to treat certain forms of cancer. This biopharmaceutical drug has gained the attention of researchers and clinical professionals throughout the People's Republic of China who are observing the drug for potential replacement of surgery and radiation therapy for cancer. Potentially, over 8 million lives can be saved each year in the People's Republic of China by this drug.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanc
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
2. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
3. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
4. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
5. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
6. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
7. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
8. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
9. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
10. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
11. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ) ... with Novartis Pharma AG to acquire worldwide rights to ... development.  This agreement is conditional on the closing of transactions ... 2014, which are expected to close in the first ...
(Date:1/22/2015)... Bedford, NH (PRWEB) January 22, 2015 ... offers a table top laboratory homogenizer, the PandaPLUS 2000, ... nanoparticles, nanodispersions, nanoemulsions , and cell disruption . ... processing dairy products, fruit juices, liquid food, food additives ...
(Date:1/22/2015)... January 22, 2015 Crystal Diagnostics (CDx) Xpress ... it has received AOAC-PTM Certifications for the six non-O157 Shiga ... O145; collectively referred to as STEC or the “Big-6”) as ... forming unit (cfu) per 325 g of raw ground beef ...
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... Pivotal Study in, Rituximab Refractory Follicular Non-Hodgkin,s lymphoma ... Number ... Genmab A/S (OMX:,GEN) announced today it has amended the design ... follicular,non-Hodgkin,s lymphoma (NHL) to a single arm trial that will ...
... May Help Increase Appropriate Early Use in Acute Coronary Syndrome ... ... 27 ,Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb,Company (NYSE: ... approved a supplemental new drug application,(sNDA) for a 300mg tablet of the ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), ... commercializing proprietary product candidates for the treatment,of ... data from,preclinical studies of ANX-514 (docetaxel emulsion) ... Cancer Research (AACR), National Cancer,Institute (NCI) and ...
Cached Biology Technology:Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study 2Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study 3FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 2FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 3FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 4FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate) 5ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 2ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 3ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference 4
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics Agency ... detect and prevent counterfeit microcircuits from entering into its ... an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. The ... increasing their reliability throughout the supply chain. The new ...
(Date:12/15/2014)... and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced ... 2015-2019" report to their offering. ... a technology used for the identification of individuals. Facial ... person such as nose, jaw edges, mouth, and the ...
(Date:12/10/2014)... Dec. 8, 2014 You,ve been here before: you desperately need ... password, site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure security company, ... to the frustration that comes with usernames, passwords and PINs – ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Adults undergoing bariatric surgery who are more physically ... and to have recently received medication or counseling ... counterparts, according to new research led by the ... "Typically, clinical professionals manage their patients, ...
... assortment of amphibian species living in a pond, the more ... a parasitic infection that can cause severe deformities, including the ... the University of Colorado Boulder. The findings, published ... idea that greater biodiversity in larger-scale ecosystems, such as forests ...
... Neil Hunter,s laboratory in the UC Davis College of Biological ... sexual reproduction shuffles genes while making sure sperm and eggs ... sexual reproduction is that a fertilized egg gets half its ... one partner in each pair of chromosomes. We humans have ...
Cached Biology News:Physical activity linked to lower rates of depression in bariatric surgery patients 2Physical activity linked to lower rates of depression in bariatric surgery patients 3CU-Boulder amphibian study shows how biodiversity can protect against disease 2CU-Boulder amphibian study shows how biodiversity can protect against disease 3CU-Boulder amphibian study shows how biodiversity can protect against disease 4Clues to chromosome crossovers 2
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
... clear, APET plastic tray. Ideal for staining ... trays used for multipurposes. Pour spouts in ... marker or label may be used for ... on rockers or shakers for staining several ...
ID clarifier: non-treated with lid...
... Staccato Series of systems provide fast and reliable scalable ... drug development laboratories. Staccato systems are available in three ... Systems Series. ... All Staccato ...
Biology Products: